Cell Platforms

What are HLA-matched cell line platforms?

Cell lines are created from patient-derived blood and tumor tissue. Our cell platforms are developed from the same patient and were HLA-typed to ensure they are from the same patient.

Advantages of HLA-matched CTL and Tumor Cell Lines

HIGHER SPECIFICITY

Higher specificity results in exquisite sensitivity between the TILs and tumors, resulting in an increased ability to detect the impact factors within the tumor micro-environment that could be masked by allogeneic responses.

CHARACTERIZED

Highly characterized tumors. Ideal to studying effects and changes in response to a drug candidate.

ESTABLISHED DATA WITH APPROVED DRUGS

Established data with approved checkpoint and targeted drug candidates for comparative and combination studies.

REPEAT STUDIES ACROSS ASSAY FORMATS

A standardized and reproducible system which with one can assess immune responses across various platforms.

BROAD SPECTRUM APPLICATIONS IN CANCER

Leverage the readouts on mechanism and function and extend applications into other tumor types.

Studies Conducted Using HLA-matched CTL and Tumor Cell Lines

Evaluate the ability of drug candidates to induce cytotoxicity in autologous tumor cell lines by measuring cell viability or apoptosis.

Assess the activation and proliferation of autologous CTLs in response to drug candidates, which can indicate their potential to enhance immune responses against tumor cells.

Determine the ability of autologous CTLs to recognize and kill tumor cells in the presence of drug candidates, evaluating their efficacy in boosting immune-mediated tumor cell destruction.

Study the effect of drug candidates on immune checkpoint molecules, such as PD-1, PD-L1, or CTLA-4, in autologous CTLs and tumor cells, assessing their potential to modulate immune checkpoint pathways.

Evaluate the impact of drug candidates on the migration and invasion of autologous tumor cells, providing insights into their potential to inhibit tumor metastasis.

Investigate the modulation of specific signaling pathways, such as MAPK or PI3K/AKT, in autologous CTLs or tumor cells upon exposure to drug candidates, identifying their mechanism of action.

Assess the ability of autologous tumor cells to present antigens to CTLs in the presence of drug candidates, examining their impact on antigen processing and presentation.

Determine the susceptibility of autologous tumor cells to drug candidates, exploring their potential to overcome drug resistance mechanisms and induce tumor cell death.

Investigate the synergistic effects of drug combinations involving autologous CTLs, tumor cells, and other treatment modalities, assessing their combined efficacy.

Previous tab Next tab